Document:

Exhibit 10.4

 

Execution Version

 

AMENDMENT TO 

 

CLINICAL TRIAL AGREEMENT

 

This Amendment
To Clinical Trial Agreement (the "CTA Amendment") is made and entered into effective as of July 8, 2015 (the
"CTA Amendment Effective Date") by and between Putney Drug Corp., a Nevada corporation having a place of business
at 617 Detroit Street, Suite 100, Ann Arbor, MI, 48104 ("Company"), and The Regents of the University of California,
a constitutional California corporation, on behalf of its Los Angeles campus, with an address at David Geffen School of Medicine
UCLA Clinical Trials Administration Office, 10911 Weybeurn Avenue, 3rd Floor, Los Angeles California 90095-7170 ("Institution"
or "The Regents"), to amend the terms of that certain Clinical Trial Agreement between Company and Institution, originally
dated as of April 29, 2010 (the "CTA"). Company and Institution may be referred to herein individually as a "Party",
and collectively as the "Parties".

 

WHEREAS, the Parties are also parties to that
certain Exclusive License Agreement dated as of July 11, 2005 (as amended to date, the "License Agreement"), and issues
have arisen concerning certain of the Parties' respective rights and obligations under the CTA and under the License Agreement;
and

 

WHEREAS, certain additional intellectual property
relating to the subject matter of the License Agreement has been created at Institution, and the Parties wish to expand their relationship
to cover such additional intellectual property and also to resolve the above issues, in part by amending the License Agreement
to provide (among other things) for increased economic consideration to the Institution, and by amending the CTA as provided in
the terms and conditions set forth below;

 

NOW, THEREFORE, in consideration of the above
premises and the mutual promises contained herein, the Parties agree as follows:

 

1.            The
CTA is hereby amended to add new Section 1.0 entitled "Definitions", added before Section 1.1, and reading in its entirety
as follows:

 

"1.0           Definitions.
Capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings ascribed to such terms in the
License Agreement . The following capitalized terms shall have the following meanings as used in this Agreement:

 

"Deliverables" has the meaning set forth
in Section 3.1 hereof.

 

"Study" means the human clinical study
conducted under the protocol entitled "A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multilple
Sclerosis (RRMS)", protocol number NCT00451204.

 

"Field of Use" has the meaning ascribed
in the License Agreement.

 

    	 

    	 

    

  

Execution Version

 

"IND" means
IND #55,288, as it relates to the Study.

 

2.            Section 3.1 of the CTA is hereby amended to read in its entirety
as follows:

 

"3.1           Institution
shall own all data resulting from the Study. Notwithstanding anything to the contrary, the Deliverables set forth herein shall
not contain any Institution or its subsite's (i) patient medical records, or (ii) source documentation as that term is defined
in Section 1.52 of the ICH E6 Guidelines to the extent that Applicable Laws prevent the disclosure thereof to Company. As soon
as reasonably practicable, allowing a reasonable amount of time for performing redactions and other required preparation, following
Study Conclusion, Institution shall provide to Company: (a) complete (except for the redactions as provided below) and accurate
copies of all patient case report forms generated under the Study not later than October 1, 2015; (b) a complete copy (except for
the permitted redactions as provided below) of any electronic Study database created by (or on behalf of) Institution based on
the patient case report forms that includes all the data elements as compiled therein, generated in performance of the Study, which
shall include any other data and results from the Study included in any such database, not later than August 1, 2015; (c) a complete
copy (except for the permitted redactions as provided below) of all the MRI data resulting from the Study, including a copy of
the electronic database containing such images; (d) copies of all cognition, gray matter and any other data and results generated
or created under the Study as generated or extrapolated from the patient case report forms; (e) a detailed report setting forth
all accomplishments and findings of the Study; (f) a copy of all analyses of the patient case report forms and/or of any other
Study data and results performed by or on behalf of the Institution or Principal Investigator; (g) the complete analysis (the “MRI
Analysis”) of a third party specified by Company, which Institution has no reasonable and significant objection (based solely
on the fact the retention of the third party consultant would violate any law, regulation, ruling of a court or agency, contractual
agreement, or written Institution policy) that is hired as a consultant by Institution and as part of its research team, and which
consultant will have full access to all the MRI data resulting from the Study, including a copy of the electronic database containing
such images, and will conduct the analysis as generally specified by Company, such MRI data being made available not later than
August 1, 2015 (costs of the third party consultant will be paid by Company); (h) complete copy of the actual analysis of the MRI
data resulting from the Study existing as of the CTA Amendment effective date, provided to Company by July 10, 2015 (collectively,
all the foregoing, the "Deliverables"). The data and information in subclauses (a)-(d) above shall be redacted to remove
patient identifying information as needed to comply with HIPAA and CMIA, and with the understanding the the reports or analyses
delivered under subclauses (e)-(g) above shall not contain patient identifying information. The databases in clause (b) and (c)
shall be provided in an electronic form that is reasonably acceptable to Company (including being transmittable, reproducible and
usable (using standard database tools) at a dedicated location on Institution's site, and, if possible using reasonable effort,
via a secure internet connection). The required redaction of Study data in (c) will occur if requested by Company, and will not
be completed by August 1, 2015. The Institution shall use reasonable diligence to complete the required redaction. Institution
further acknowledges that Company shall engage a third party consultant (selected by Company after consulting with Institution)
to perform analysis of the Deliverables, and Institution agrees to provide such third party consultant reasonable access to the
Deliverables in Institution's possession (to the extent not provided to such consultant directly by Company) for such analysis.
Institution and Principal Investigator have no commitment or obligation to continue any analysis of the data from the Study."

 

    	 

    	 

    

  

Execution Version

 

3.             Section 3.2 of the CTA is hereby amended to read in its entirety
as follows:

 

"3.2           The
Deliverables provided to Company shall be held in confidence by Company (and its affiliates and sublicensees) until publication
of results of the Study by Institution pursuant to Article 4 below. It is agreed by Institution that (without limitation) publication
of an article substantially containing the information in the draft article provided to Company by Institution counsel on or about
June 30, 2015 shall constitute such publication of Study results. After such publication of Study results, Company shall be free
to disclose publicly information in the Deliverables in compliance with all applicable laws and Study consent forms. Institution
shall provide Company with copies of Institutional Review Board approved informed consent templates for the Study, and, at the
request of Company within the next 2 years from the CTA Amendment Effective Date, redacted copies of the Study informed consent
forms in the possession of the Institution, or study sites, with fully-burdened costs and overhead to be pay by the Company. It
is agreed, however, that under no circumstances will Company state or overtly imply in any publication or other published announcement
that Institution has approved any product. Institution hereby grants Company (and its Affiliates and Sublicensees, as defined in
the License Agreement) the non-exclusive perpetual, transferable rights, sublicenseable through multiple tiers of sublicensees,
to use all information in the Deliverables for all purposes relating to development, registration and commercialization of Licensed
Products in the Field of Use, but subject to the foregoing confidentiality obligations (prior to publication of the Study results),
and in compliance with all applicable laws and Study consent forms. Institution hereby grants Company (and its Affiliates and Sublicensees,
as defined in the License Agreement) the rights of reference to the Institution's IND for the Study and the Deliverables for the
development, registration and commercialization of products licensed to Company under the License Agreement in accordance with
the terms in Section 3.4. Initial Study data validation and review shall be done on behalf of Company promptly after receipt of
the Deliverables by a third party consultant selected by and employed with Company (after consultation with UCLA), separate and
apart from consultant hired to Institution’s research team as set forth in 3.1 above. Company shall own all reports, results
and analysis resulting from its consultant's analysis and review (the "Analysis") and the MRI Analysis of the third party
in 3.1 (g), and Institution assigns to Company its entire rights in the Analysis (but excluding any patent rights and any rights
in the Study data). Institution covenants that it shall not conduct any review or analysis of the MRI Analysis until the date 90
days after delivery of the MRI Analysis to Company under Section 3.1(g). Company and its affiliates and sublicensees may use such
Analysis with respect to Estriol in Field of Use, shall have the rights to disclose it to its Affiliates and Sublicensees (as those
terms are used in the License Agreement), and to entities whom are believed in good faith to be potential development partners,
subject to appropriate confidentiality obligations and other identified state and federal regulatory constraints, including but
not limited to, HIPAA and CMIA. Company shall disclose the Analysis to the Institution in confidence, and shall ensure that the
Deliverables and Analysis are not publicly disclosed until Principal Investigator is given a reasonable opportunity to publish
on the clinical data, subject to the right of Company to remove Company Proprietary Information, and to request that patent applications
be filed by the Regents based on any data, as provided in Article 4 below. Notwithstanding the foregoing, the Institution can use
the Analysis in order to ensure the health and safety of the subjects enrolled in the Study."

 

    	 

    	 

    

  

Execution Version

 

4.            The
CTA is hereby amended to add a new Section 3.3, reading in its entirety as follows:

 

"3.3           Company
shall reimburse The Regents for its fully-burdened costs, as budgeted by the Parties in advance, directly incurred in preparing
the databases and materials for delivery to Company (as set forth in Section 3.1 above), plus overheard of twenty-six percent (26%),
such reimbursement not to exceed the budget reasonably agreed to by the Parties. Such costs include but are not limited to the
costs incurred to redact patient identifying information from databases and patient case report forms, and (if applicable) training
Company or a third party consultant to use the databases. The Institution shall invoice Company promptly for such costs, accompanied
by such supporting documentation for such costs as Company may reasonably request."

 

    	 

    	 

    

  

Execution Version

 

5.            The CTA is hereby amended to add a new Section 3.4, reading
in its entirety as follows:

 

"3.4           The
Regents hereby grant to Company a right to reference for use in the Field of Use (including in connection with all development
and approval activities on Licensed Products) to all regulatory documentation filed with respect to the Study, filed with the FDA
regarding the IND, and all information therein, subject to the redaction of patient identifying information. The Institution shall
provide to Company copies of all such regulatory documentation filed with the FDA under the IND upon reasonable request, which
shall redacted in order to comply with laws and regulations regarding privacy of patient information, such redactions at Company's
sole expense, including 26% overhead at the Institution, and subject to applicable law or regulation. The Regents will use reasonable
good faith efforts to determine if they can agree not to grant to any other commercial party a right of reference to any such regulatory
documentation filed with the FDA regarding the FDA in the Field of Use, to the extent permitted by law, contractual obligations,
and The Regents’ policy, for a period of up to 5 years. At Company's request, and provided that Institution can so agree,
The Regents will provide Company such written agreement, for the maximum period (not to exceed 5 years) that The Regents can so
agree not to grant such rights to other commercial parties." Principal Investigator represents that there were no foreign
regulatory filings relating to the Study.

 

6.           Section
7.4 of the CTA is hereby amended to add the following sentence to the end of the Section: "Notwithstanding the above restrictions,
Institution agrees that Company (and its Affiliates and Sublicensees (as that term is used in the License Agreement) may use all
information in the Deliverables as permitted in Section 3.2.

 

7.           Section
7.5 of the CTA is hereby amended to add the following phrase to the end of the Section: " (with the understanding that Section
3.2 grants Company (and its Affiliates and Sublicensees (as that term is used in the License Agreement) specific consent to disclose
or release information in the Deliverables as provided in such Section)".

 

8.           Section
8.2 of the CTA hereby amended to include the following subsection:

 

Section 8.2(c). To the extent Field of Use in the License
Agreement is narrowed or expanded, the Field of Use in this Agreement shall narrow or expand in the same manner. To the extent
the License Agreement is terminated, the CTA shall terminate as well.

 

    	 

    	 

    

  

Execution Version

 

9.            Section
8.4 of the CTA is hereby amended to read in its entirety as follows:

 

The obligations of the Parties under Sections 1.1 ,1.3,
1.4, 2.1, 3.1, 3.2, 3.4, 4.1, 5.1-5.6, 6.1, 7.1-7.8, 9.1, 9.2, 10.1, 11,2, and 11.4-11.7 shall survive any termination this Agreement,
except that any exclusive rights that may be granted pursuant to section 3.4 shall become non-exclusive if a termination occurs
pursuant to the last sentence of Section 8.2(c).

 

10.          The Parties
hereby agree to negotiate diligently, reasonably and in good faith with each other and to agree on a further amendment to the CTA
(as amended by this CTA Amendment) that (a) provides clearer definition of the terms for the consultant under Section 3.1(g) above;
and (b) provides terms for redaction of the MRI database, as contemplated in Section 3.1(c) above.

 

 

11.          Except
as modified by the amendments and other agreements as provided in this CTA Amendment, all the terms and provisions of the CTA are
and shall remain in full force and effect. This CTA Amendment is deemed incorporated into and made part of, and governed by the
applicable terms of, the CTA.

 

12.          This CTA
Amendment is effective only if (a) it is fully executed by both Parties and (b) both Parties fully execute the Sixth Amendment
to the License Agreement and the Release Agreement of equal date with this CTA Amendment.

 

[Signature Page Follows]

 

    	 

    	 

    

  

Execution Version

 

IN WITNESS WHEREOF, the Parties have caused this CTA Amendment to
be executed by their duly authorized representatives:

 

Putney Drug Corp. 

 

	By: 	/s/ Jeffrey Riley	 
	 	 	 
	Name:  	Jeffrey Riley	 
	 	 	 
	Title: 	CEO, President and Director

	 
	 	 	 
	The Regents of the University of California	 
	 	 	 
	By:	/s/Helene Orescan	 
	 	 	 
	Name:	Helene Orescan	 
	 	 	 
	Title: 	Director CTAO	 
	 	 	 
	Read & Acknowledged Principal Investigator	 
	 	 	 
	By: 	Rhonda Voskuhl MD	 
	 	 	 
	Name: 	Rhonda Voskuhl MD	 
	 	 	 
	Title: 	Professor UCLA Dept of NeurologyExhibit 10.01 

 

RESCISSION AGREEMENT

 

THIS
RESCISSION AGREEMENT, dated as of June 30, 2015 is made by and among Freedom Seed & Feed, Inc., a Nevada corporation (“FSF”),
the shareholders of FSF set forth on Schedule I hereto (the “FSF Shareholders”), Mountain High Acquisitions
Corp., a Colorado corporation (“MYHI”) and the shareholders of MYHI set forth on Schedule II hereto (the “MYHI
Shareholders” and with the FSF Shareholders, the “Shareholders”).
FSF, MYHI and the Shareholders are at times referred to in this Rescission Agreement (the “Agreement”) individually
as a “Party” and collectively as the “Parties.”

 

WHEREAS,
on March 31, 2015, the Parties entered into a share exchange agreement pursuant to which the FSF Shareholders exchanged (the “Exchange”)
all 75,000 of the issued and outstanding shares of FSF, no par value per share (the “FSF Shares”) for an aggregate
of 29,429,000 shares of common stock, par value $0.0001 per share, of MYHI (the “MYHI Shares” and
with the FSF Shares, the “Shares”);

 

WHEREAS, on May 19, 2015, the
Parties entered into a First Amendment to Share Exchange Agreement (as so amended, the “Exchange Agreement”)
that, inter alia, increased the number of FSF Shares to be received by the FSF Shareholders to 31,429,000; and

 

WHEREAS, the Parties have amicably
determined that it is in their collective best interest to: (i) rescind the Exchange Agreement, including but not limited to the
exchange of FSF Shares for MYHI Shares, and (ii) provide for such additional agreements as are set forth herein.

 

NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, the Company and each Shareholder agree as follows:

 

1. Surrender of MYHI Shares

 

a. The holders of
MYHI Shares hereby cancel, waive, relinquish and disclaim in all respects any and all claims and/or rights to record or beneficial
ownership in and to the MYHI Shares set forth on Schedule A next to each such undersigned person’s name as of June 30, 2015
(the “Closing Date”).

 

b. The MYHI Shares
shall be delivered to MYHI at the address indicated below for notices, together with executed stock powers promptly following execution
of this Agreement, but no later than August 1, 2015. Notwithstanding the obligation to deliver such MYHI Shares for cancellation,
the Secretary of MYHI shall, on the Closing Date, record such cancellations and shall have the full power and authority to direct
the transfer agent for MYHI to cancel such MYHI Shares on the books and records of the MYHI as attorney-in-fact for the holders
of such MYHI Shares cancelled hereby or as transferred hereby.

 

2. Surrender of FSF Shares

 

a. MYHI, as the
holder of all FSF Shares hereby cancels, waives, relinquishes and disclaims in all respects any and all claims and/or rights to
record or beneficial ownership in and to the FSF Shares received in the Exchange as of the Closing Date.

 

b. Executed stock
powers for the transfer of FSF Shares shall be delivered by MYHI to the FSF Shareholders care of FSF at the address indicated below
for notices promptly following execution of this Agreement, but no later than the Closing Date. Notwithstanding the obligation
to deliver such executed stock powers, the Secretary of FSF shall, on the Closing Date, record such transfer and shall have the
full power and authority to cancel MYHI’s ownership of the FSF Shares on the books and records of FSF as attorney-in-fact
for the holders of such FSF Shares as transferred hereby.

 

3.Cooperation

 

a.Each of the
Parties shall continue to provide such information to the other Parties as may be necessary for such Party to comply with its continuing
reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or as otherwise
reasonably requested. Each of MYHI and FSF shall, at all times, provide the requesting Party access to the books and records of
the other Party on reasonable advance notice to the extent they are in possession of such.

 

b.All information
regarding the business of FSF including, without limitation, financial information that FSF provided to MYHI during MYHI due diligence
investigation of FSF will be destroyed or, if incapable of being destroyed, kept in strict confidence by MYHI and will not be used,
dealt with, exploited or commercialized by MYHI or disclosed to any third party without the prior written consent of FSF.

 

4.Representation Regarding Non
assignment; Releases

 

a. Each of the Parties
represents and warrants that he, she or it has not assigned, transferred, sold, or pledged, any Share or any claim or claims that
he, she or it has, has had, or may have, against any of the other Parties and each of the Parties understands and acknowledges
that the other Parties are relying on the aforesaid warranty and representation.

 

b. In consideration
of the consideration and obligations described in this Agreement, FSF hereby releases and discharges MYHI and the MYHI Shareholders,
and their respective heirs, executors, successors, assigns, agents and trusts (the “MYHI Releasees”), from and
against any and all actions, causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties,
covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, extents, executions, claims,
and demands, whatsoever, in law, admiralty, or equity, which each or any of the MYHI Releasees and their respective representatives,
agents, attorneys, predecessors, successors, insurers, administrators, heirs, executors and assigns, has ever had, now has, or
hereinafter can, shall, or may have, for, upon, or by reason of, any matter, cause, or thing, whatsoever, whether known or unknown,
from the beginning of the world to the day of the date of this Agreement (other than as a result of any breach of any obligation
set forth in this Agreement).

 

c. In consideration
of the consideration and obligations described in this Agreement, MYHI and the MYHI Shareholders hereby release and discharge FSF
and the FSF Shareholders, and their respective heirs, executors, successors, assigns, agents and trusts (the “FSF Releasees”),
from and against any and all actions, causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills,
specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, extents, executions,
claims, and demands, whatsoever, in law, admiralty, or equity, which each or any of the FSF Releasees and their respective representatives,
agents, attorneys, predecessors, successors, insurers, administrators, heirs, executors and assigns, has ever had, now has, or
hereinafter can, shall, or may have, for, upon, or by reason of, any matter, cause, or thing, whatsoever, whether known or unknown,
from the beginning of the world to the day of the date of this Agreement (other than as a result of any breach of any obligation
set forth in this Agreement).

 

d. The Parties agree
that they will not publicly or privately disparage or criticize FSF, MYHI or the any of the Shareholders, or any of their partners,
shareholders, members, directors, officers, agents, attorneys or employees.

 

5. Disclaimer of Rights

 

Neither FSF nor any of the FSF Shareholders
shall have any right to any of the cash, claims, assets or business of MYHI. Neither MYHI nor any of the MYHI Shareholders shall
have any right to any of the cash, claims, assets or business of FSF.

 

6.Indemnification

 

a. MYHI will
indemnify, defend, and hold harmless, to the full extent of the law, FSF and the FSF Shareholders, from, against, and in respect
of any and all any and all liabilities, losses, damages, costs and expenses (including reasonable attorney’s fees and costs)
(collectively, “Losses”), asserted against, relating to, imposed upon, or incurred by FSF or the FSF Shareholders
by reason of, resulting from, based upon or arising out of the breach by MYHI of any representation or warranty of MYHI or the
MYHI Shareholders contained in or made pursuant to this Agreement or any certificate or other instrument delivered pursuant to
this Agreement; or the breach or partial breach by MYHI or the MYHI Shareholders of any covenant or agreement of MYHI or the MYHI
Shareholders made in or pursuant to this Agreement or any certificate or other instrument delivered pursuant to this Agreement.

 

b. FSF will
indemnify, defend, and hold harmless, to the full extent of the law, MYHI and the MYHI Shareholders, from, against, and in respect
of any and all any and all Losses asserted against, relating to, imposed upon, or incurred by MYHI or the MYHI Shareholders by
reason of, resulting from, based upon or arising out of the breach by FSF of any representation or warranty of FSF or the FSF Shareholders
contained in or made pursuant to this Agreement or any certificate or other instrument delivered pursuant to this Agreement; or
the breach or partial breach by FSF or the FSF Shareholders of any covenant or agreement of FSF or the FSF Shareholders made in
or pursuant to this Agreement or any certificate or other instrument delivered pursuant to this Agreement.

 

7. Miscellaneous

 

a.Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns.

 

b.Governing
Law; Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by and construed under the laws of the State of Nevada
without regard to the choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of
the state and federal courts sitting in the State of Nevada for the adjudication of any dispute hereunder or in connection herewith
or therewith or with any transaction contemplated hereby or thereby, and hereby irrevocably waives any objection that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

c.Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each party
to this Agreement will be entitled to specific performance hereunder. Accordingly, the Parties agree that, in addition to any other
remedies available to it at law or in equity, any party shall be entitled to seek injunctive relief to enforce the terms of this
Agreement.

 

d.Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

e.Counterparts/Execution.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that
any signature is delivered by facsimile transmission or by an e-mail which contains an electronic file of an executed signature
page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an
original thereof.

 

f.Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

g.Notices.
All notices, requests, demands, and other communications hereunder shall be in writing and delivered personally or sent by registered
or certified United States mail, return receipt requested with postage prepaid, or by telecopy or e-mail, addressed as follows:
(i) such address as appears on the books and records of MYHI with respect to the MYHI Shareholders, and in the case of MYHI, the
most recent address for notices set forth from time to time as the office of MYHI in its SEC filings and reports, and (ii) such
address as appears on the books and records of FSF with respect to the FSF Shareholders, and in the case of FSF, to 840 Lynn Road,
Lexington, KY 40504. Any party hereto may change its address upon 10 days’ written
notice to any other party hereto.

 

h.Expenses.
The parties hereto shall pay their own costs and expenses in connection herewith.

 

i.Attorneys’
Fees.
In the event that it should become necessary for any party entitled hereunder to bring suit against any other party to this Agreement
for a breach of this Agreement, the parties hereby covenant and agree that the prevailing party shall be entitled to recover all
reasonable attorneys’ fees and costs of court incurred in
connection with any such dispute

 

j.Entire
Agreement; Amendments. This Agreement constitutes the entire agreement between the parties with regard to the subject matter
hereof and thereof, superseding all prior agreements or understandings, whether written or oral, between or among the parties.
No amendment, modification or other change to this Agreement or waiver of any agreement or other obligation of the parties under
this Agreement may be made or given unless such amendment, modification or waiver is set forth in writing and is signed by all
parties to this Agreement. Any waiver or consent shall be effective only in the specific instance and for the specific purpose
for which given.

 

k.Headings.
The headings used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this
Agreement.

 

l.Construction.
Words of any gender used in this Agreement shall be held and construed to include any other gender, and words in the singular number
shall be held to include the plural, and vice versa, unless the context requires otherwise.

 

m.Counterparts;
Facsimile Signatures. This Agreement may be executed in counterparts, all of which shall be considered one and the same agreement
and shall become a binding agreement when one or more counterparts have been signed by each of the Parties hereto and delivered
to the other Parties, whether in facsimile or hard copy.

 

 

 

[Remainder of page intentionally left
blank.]

    	 

    	 

    

 

 

IN WITNESS WHEREOF the parties have
executed this Agreement effective as of the day and year first above written.

 

MOUNTAIN HIGH ACQUISITIONS CORP.

 

/s/Alan Smith

Name: Alan Smith

Title: Chief Executive Officer 

 

MYHI SHAREHOLDERS

 

/s/ Alan Smith

Name: Alan Smith

Shares Owned: 6,000,000

Percent of Class: 9.2%

 

 

 

/s/Rick Stifel

Name: Rick Stifel

Shares Owned: 250,000

Percent of Class: 0.4%

 

 

FREEDOM SEED & FEED, INC. 

 

 

 

/s/David Hadland

Name: David Hadland

Title: President

 

 

 

    	 

    	 

    

 

FSF SHAREHOLDERS SIGNATURES

 

	NAME AND ADDRESS	SIGNATURE	PERCENT OF OWNERSHIP
	Shares	Percent
	
        Living 360

        Saeb Jannoun

        5523 Rawls Road

        Tampa, FL 33625

         
	 	4,500	6%
	
        Axiom Financials, Inc.

        Darren Bankston

        327 Dahlonega Road

        Ste 1701 B

        Cumming, GA 30040

         
	 	395	0.53%
	
        Koki Motors

        Mike Jrab

        9432 Cavendish Drive

        Tampa, FL 33626

         
	 	2,487	3.32%
	
        Micaddan Marketing Consultants, LLC

        Alan Rosenthal

        1141 Chanticleer

        Cherry Hill, NJ 08003

         
	 	592	0.79%
	
        Andy Sauder

        329 High Street

        Santa Cruz, CA 95060

         
	 	197	0.26%
	
        Street Capital

        300 Colonial Center Parkway

        Ste 260

        Roswell, GA 30076

         
	 	3,750	5.00%
	
        David Hadland

        840 Lynn Road

        Lexyington, KY 40405

         
	 	31,538	42.05%
	
        Michael Lewis

        840 Lynn Road

        Lexyington, KY 40405

         
	 	31,538	42.05%
	 	 	 	75,000	100.00%

 

 

 

    	 

    	 

    

 

SCHEDULE I

MYHI SHAREHOLDER

 

	Beneficial Owner	
         

        Number 

         

        
	Title of Class
	 	
         

        6,000,000
	Common
	Alan Smith – 
	Current Chief Executive Officer
	 
	Total 	6,000,000	Common

 

 

 

 

    	 

    	 

    

 

SCHEDULE II

FSF SHAREHOLDERS

 

	NAME AND ADDRESS	
        SHARES

         

	
        NUMBER

         
	CLASS
	
        Living 360

        Saeb Jannoun

        5523 Rawls Road

        Tampa, FA 33625

         
	4,500	Common
	
        Axiom Financials, Inc.

        Darren Bankston

        327 Dahlonega Road

        Ste 1701B

        Cumming, GA 30040

         
	395	Common
	
        Koki Motors

        Mike Jrab

        9432 Cavendish Drive

        Tampa, FL 33626

         
	2,487	Common
	
        Micaddan Marketing Consultants, LLC

        Alan Rosenthal

        1141 Chanticleer

        Cherry Hill, NJ 08003

         
	 	Common
	
        David Sauder

        329 High St

        Santa Cruz, CA 95060

         
	197	Common
	
        Street Capital

        300 Colonial Center Parkway

        Ste 260

        Roswell, GA 30076

         
	3,750	Common
	
        David Hadland

        840 Lynn Road

        Lexington, KY 40405

         
	 	Common
	
        Michael Lewis

        403 North 3rd St

        Danville, KY 40422

         
	 	Common
	TOTAL	75,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]